MBL2 and X-linked agammaglobulinemia: Again IgM seemed to play a central role as the patient with no IgM binding (X-linked agammaglobulinemia) had low classical pathway activity despite measurable IgG binding (together C1q and MBL inhibition did not add up to 100% as they were not applied simultaneously and possibly due to the alternative pathway amplification).